Deciphera Pharmaceuticals Stock News

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH)s traded shares stood at 0.93 million during the last session, with the companys beta value hitting 1.49. At the close of trading, the stocks price was $8.64, to imply an increase of 4.10% or $0.34 in intraday trading. The DCPH shares 52-week high remains $61.92, putting it -616.67% down since that Boom Or Bust: What Does The Future Hold For Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) Stock? Read More »

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Equities research analysts at SVB Leerink lowered their FY2021 earnings estimates for shares of Deciphera Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 30th. SVB Leerink analyst A. Berens now forecasts that the company will earn ($5.29) per share for the year, down from their []

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Piper Sandler cut their FY2021 earnings estimates for Deciphera Pharmaceuticals in a research report issued on Tuesday, November 30th. Piper Sandler analyst C. Raymond now anticipates that the company will post earnings of ($5.35) per share for the year, down from their previous forecast of ($5.09). Piper Sandler has a [] The post Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) to Post FY2021 Earnings of ($5.35) Per Share, Piper Sandler Forecasts appeared first on ETF Daily News .

Wells Fargo & Company MN cut its holdings in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) by 60.6% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 216,114 shares of the companys stock after selling 332,876 shares during the period. Wells Fargo & Company MNs holdings in Deciphera Pharmaceuticals were worth $7,912,000 at the end of the []

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Research analysts at Jefferies Financial Group cut their FY2021 earnings estimates for Deciphera Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 30th. Jefferies Financial Group analyst E. Yang now anticipates that the company will post earnings of ($5.49) per share for the year, down from []

Blueprint Medicines' (BPMC) Ayvakit, which has been approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. However, stiff competition remains a

The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pipeline updates from Vertex (VRTX) and Amgen (AMGN) and other acquisition and regulatory updates have been the biotech sector's few key highlights during the past week.

Deciphera (DCPH) announces a corporate restructuring plan to prioritize development of vimseltinib and DCC-3116, streamline commercial operations and reduce workforce by almost 35%. Shares rise.

The company announced a comprehensive restructuring program.

Deciphera is a biotech full of hope but lagging on financial performance. The recent selloff in DCPH stock is justified by its poor trials.

The company announced a comprehensive restructuring program.

Deciphera is a biotech full of hope but lagging on financial performance. The recent selloff in DCPH stock is justified by its poor trials.